{"filings":[{"id":2060846,"accession_number":"0000059478-26-000077","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2026-08-05T11:05:09+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lilly Q2 revenue up 48% to $23.0B; raises full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2026 revenue $22,974M (+48% YoY); reported EPS $7.94 (+26%), non-GAAP EPS $8.38 (+33%).","Full-year revenue guidance raised to $85.0-87.0B; non-GAAP EPS guidance $35.50-$36.50 (up $2.78 midpoint).","Q2 EPS includes $3.03/share of acquired IPR&D charges from business development activity.","Completed acquisitions of Orna, Ajax, Centessa, Kelonia; post-quarter added infectious disease assets and AtaiBeckley.","Committed $4.5B to expand Indiana manufacturing sites; retatrutide Phase 3 data complete for global registrations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":555321,"accession_number":"0001193125-26-232707","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2026-05-20T20:30:32+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lilly completes $9B multi-tranche debt offering tied to Centessa acquisition","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Completed $9.0B aggregate principal debt offering across eight tranches of floating and fixed-rate notes due 2026-2066.","Net proceeds of ~$8.94B after underwriting discounts; proceeds intended for general corporate purposes including the Centessa Acquisition.","Interest rates: floating at SOFR+0.350% (2028) or +0.460% (2029); fixed rates from 4.150% to 5.700%.","Certain notes (2029 floating, 2029/2031/2033/2036 fixed) subject to mandatory redemption at 101% if Centessa Acquisition not closed by March 31, 2027.","Notes issued under existing indenture; underwriters include Morgan Stanley, Citigroup, Deutsche Bank, Goldman Sachs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98253,"accession_number":"0000059478-26-000048","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Lilly shareholders re-elect directors, reject board declassification and supermajority proposals","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Four directors (Bertozzi, Kaelin, Moeller, Ricks) elected; say-on-pay approved with 95.7% of votes cast.","Board declassification proposal failed: 70.4% of outstanding shares voted for, short of 80% requirement.","Supermajority elimination proposal also failed: 70.3% for, below 80% threshold.","Shareholder proposal for independent board chair rejected (33.7% for).","Ernst & Young ratified as auditor with 94.7% of votes cast."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98252,"accession_number":"0000059478-26-000043","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lilly Q1 revenue $19.8B (+56% YoY), raises FY guidance, FDA approves Foundayo","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2026 revenue $19.8B (up 56% YoY); reported EPS $8.26 (up 170%); non-GAAP EPS $8.55.","FY2026 revenue guidance raised to $82B-$85B; non-GAAP EPS guidance $35.50-$37.00.","U.S. FDA approved Foundayo (orforglipron) for obesity—first GLP-1 pill without food/water restrictions.","Acquired Orna Therapeutics, Centessa Pharmaceuticals, Kelonia Therapeutics, and Ajax Therapeutics.","Pipeline progress: positive Phase 3 for Foundayo in T2D, Jaypirca combo in CLL, and retatrutide in T2D."],"consensus_eps_estimate":null,"consensus_eps_actual":8.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":19799000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113608,"accession_number":"0000059478-26-000008","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2026-02-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lilly Q4 revenue up 43% to $19.3B; EPS $7.39 (+51%); FY2026 guidance $80-83B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $19.3B (+43% YoY); reported EPS $7.39 (+51%); non-GAAP EPS $7.54 (+42%), both incl. $0.52 acquired IPR&D.","FY2026 guidance: revenue $80-83B; non-GAAP EPS $33.50-$35.00.","FDA approved Kwikpen for tirzepatide; filed orforglipron for obesity in US, Japan, and EU.","Positive Phase 3 results for Taltz+Zepbound combo in psoriatic arthritis and retatrutide for knee osteoarthritis.","Agreement with U.S. government to expand access to obesity medicines for millions of Americans."],"consensus_eps_estimate":null,"consensus_eps_actual":22.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":65179000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130012,"accession_number":"0000059478-25-000271","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Eli Lilly elects Carolyn R. Bertozzi to board as independent director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Carolyn R. Bertozzi, Ph.D elected to board effective Dec 8, 2025; will stand for election at May 2026 annual meeting.","Bertozzi is Anne T. and Robert M. Bass Professor of Chemistry at Stanford and HHMI Investigator.","She will serve on Science & Technology Committee and Ethics & Compliance Committee.","Board determined she is independent under NYSE standards and company guidelines.","She will participate in standard director compensation program as described in proxy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130011,"accession_number":"0000059478-25-000251","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lilly Q3 revenue up 54% to $17.6B; raises FY2025 guidance on Mounjaro/Zepbound demand","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 reported EPS $6.21 vs $1.07 YoY; non-GAAP EPS $7.02 vs $1.18.","Revenue $17.6B (up 54% YoY) driven by Mounjaro and Zepbound volume growth.","Raises FY2025 revenue guidance to $63.0-63.5B; reported EPS $21.80-22.50, non-GAAP EPS $23.00-23.70.","Pipeline: plans to submit orforglipron for obesity to global regulators by year-end after positive Phase 3 trials.","U.S. FDA approved Inluriyo (imlunestrant) for advanced/metastatic breast cancer; manufacturing expansions in VA, TX, Puerto Rico."],"consensus_eps_estimate":null,"consensus_eps_actual":15.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":45887000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146595,"accession_number":"0001193125-25-184093","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2025-08-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lilly raises $7.75B in multi-tranche debt offering; net proceeds ~$6.71B","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $7.75B across 7 tranches (floating-rate due 2028, fixed-rate due 2028-2065); closed Aug 20, 2025.","Net proceeds of approximately $6.71 billion after underwriting discounts and estimated expenses.","Key tranches: $1.25B 4.900% notes due 2035; $1B each of 4.000% due 2028, 4.550% due 2032, 5.550% due 2055, 5.650% due 2065.","Underwriting led by Citigroup, Goldman Sachs, J.P. Morgan, Mizuho, Morgan Stanley."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146594,"accession_number":"0000059478-25-000202","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lilly Q2 revenue $15.56B (+38% YoY), EPS $6.29 (+92%), raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $15.56B, up 38% YoY, driven by volume growth from Zepbound and Mounjaro.","Reported EPS $6.29, up 92%; non-GAAP EPS $6.31, up 61%, both inclusive of $0.14 IPR&D charges.","Full-year revenue guidance raised $1.5B to $60-62B; reported EPS guided $20.85-22.10; non-GAAP EPS $21.75-23.00.","Pipeline progress: positive results for orforglipron in obesity, Mounjaro SURPASS CVOT in T2D and heart disease, and Jaypirca vs Imbruvica in CLL/SLL.","Completed acquisitions of SiteOne Therapeutics and Verve Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":9.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":28286200000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":164978,"accession_number":"0000059478-25-000138","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Lilly annual meeting: directors reelected, classified board and supermajority amendments fail","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Four directors elected to three-year terms: Alvarez, Hedley, Johnson, Luciano, each with >726M votes for.","Advisory say-on-pay approved: 731.4M for, 28.0M against, 1.8M abstentions.","Ernst & Young ratified as auditor for 2025: 805.1M for, 40.8M against.","Classified board elimination failed: 658.8M for (69.5% of outstanding), below 80% threshold.","Supermajority voting elimination failed: 655.8M for (69.2% of outstanding), below 80% threshold."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":164977,"accession_number":"0000059478-25-000129","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lilly Q1 revenue up 45% to $12.73B; EPS beat; reaffirms guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $12.73B (+45% YoY) driven by Mounjaro and Zepbound volume growth.","Reported EPS $3.06 (+23%); non-GAAP EPS $3.34 (+29%), including $1.72 IPR&D charges.","Revenue guidance reaffirmed at $58.0-$61.0 billion for full-year 2025.","Pipeline: positive Phase 3 for oral GLP-1 orforglipron in T2D; approvals in oncology/immunology."],"consensus_eps_estimate":null,"consensus_eps_actual":3.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":12728500000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182691,"accession_number":"0001193125-25-025057","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Eli Lilly issues $6.5B of notes across 6 tranches; net proceeds ~$6.46B","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issues $1B 4.550% notes due 2028, $1.25B 4.750% notes due 2030, $1B 4.900% notes due 2032.","Issues $1.25B 5.100% notes due 2035, $1.25B 5.500% notes due 2055, $750M 5.600% notes due 2065.","Net proceeds of approximately $6.46B after underwriting discounts; offering closed February 12, 2025.","Notes issued under existing indenture; redemption at company's option on specified terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182690,"accession_number":"0000059478-25-000037","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lilly Q4 2024 revenue up 45% to $13.53B, EPS $4.88; 2025 guidance of $58-61B revenue","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $13.53B (+45% YoY); reported EPS $4.88 (+102%); non-GAAP EPS $5.32 (+114%).","Revenue growth driven by volume from Mounjaro and Zepbound; non-incretin revenue grew 20%.","2025 guidance: revenue $58.0-61.0B, reported EPS $22.05-23.55, non-GAAP EPS $22.50-24.00.","Pipeline: FDA approved Zepbound for OSA and Omvoh for Crohn's; Kisunla approved in China.","Board authorized $15B share repurchase program and 15% dividend increase."],"consensus_eps_estimate":null,"consensus_eps_actual":11.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":45042700000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182689,"accession_number":"0000059478-25-000005","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lilly updates 2024 revenue to ~$45B, Q4 ~$13.5B; guides 2025 revenue $58-61B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["2024 full-year revenue expected ~$45.0B, up 32% YoY and $4B above initial guidance midpoint.","Q4 2024 revenue ~$13.5B, up 45% YoY, but $400M below low end of Oct 30 guidance due to slower incretin growth and lower channel inventory.","Mounjaro Q4 revenue ~$3.5B, Zepbound ~$1.9B; non-incretin revenue grew 20% YoY.","2025 revenue guidance $58-61B, midpoint growth of 32% vs expected 2024; includes new product launches and manufacturing expansion.","Full Q4 2024 results and 2025 financial guidance to be reported on February 6, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":11.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":45042700000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199280,"accession_number":"0000059478-24-000258","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2024-11-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Eli Lilly elects P&G CEO Jon Moeller to board; Karen Walker resigns effective Dec 31","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jon Moeller, Chairman/CEO of Procter & Gamble, elected to Lilly board effective Dec 1, 2024.","Karen Walker resigns from board effective Dec 31, 2024; will collaborate on digital commercial activities in 2025.","Moeller will serve on Audit Committee and Directors and Corporate Governance Committee; stands for election at May 2026 annual meeting.","Walker's resignation not due to any disagreement with the company; she served since 2018 on Audit and Talent Committees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199279,"accession_number":"0000059478-24-000242","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lilly Q3: Revenue $11.44B (+20% YoY); EPS $1.07/$1.18; FY revenue guidance raised to $45.4-$46.0B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $11.44B, up 20% YoY; excluding $1.42B prior-year olanzapine divestiture, revenue up 42%.","Reported EPS $1.07; non-GAAP EPS $1.18, both including $3.08 acquired IPR&D charges.","Mounjaro and Zepbound drove volume growth; non-incretin revenue up 17% ex-divestiture.","FY 2024 revenue guidance raised to $45.4-$46.0B; EPS guidance $12.05-$12.55 reported, $13.02-$13.52 non-GAAP.","Positive Phase 3 data for tirzepatide (94% diabetes risk reduction) and donanemab (reduced ARIA-E)."],"consensus_eps_estimate":null,"consensus_eps_actual":6.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":31509900000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215312,"accession_number":"0000059478-24-000213","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2024-09-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Lilly appoints Lucas Montarce as EVP and CFO, effective Sept 9, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lucas Montarce, 47, promoted from president of Spain/Portugal/Greece hub to CFO, effective immediately.","He previously served as group VP, controller and CFO of Lilly Research Labs since 2021; joined Lilly in 2001.","Compensation includes $1M annual base salary and $1M target bonus; no family relationships or special arrangements.","CEO David Ricks cited Montarce's drive and integrity following an internal and external search across industries.","Montarce holds a BBA from Catholic University (Argentina) and an MBA from CEMA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215311,"accession_number":"0000059478-24-000196","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2024-08-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Lilly director Marschall S. Runge to retire from board effective Aug. 31, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Runge served on board since 2013; retirement effective Aug. 31, 2024.","No replacement named; departure not due to any disagreement with company.","Runge also retiring as CEO of Michigan Medicine effective June 30, 2025; will remain on faculty."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215310,"accession_number":"0001193125-24-200435","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Eli Lilly issues $5B in notes across five tranches with maturities from 2027 to 2064","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $750M 4.150% notes due 2027, $1B 4.200% notes due 2029, $1.25B 4.600% notes due 2034, $1.25B 5.050% notes due 2054, $750M 5.200% notes due 2064.","Net proceeds approximately $4.96 billion after underwriting discounts and expenses.","Underwriting syndicate led by BNP Paribas, Citigroup, Goldman Sachs, J.P. Morgan, and Morgan Stanley.","Notes are unsecured and may be redeemed at the company's option prior to maturity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215309,"accession_number":"0000059478-24-000185","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lilly Q2 revenue up 36% to $11.3B, raises FY revenue guidance by $3B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $11.30B (+36% YoY); reported EPS $3.28 (+68%), non-GAAP EPS $3.92 (+86%).","FY revenue guidance raised $3B; reported EPS raised $2.05 to $15.10-15.60; non-GAAP EPS raised $2.60 to $16.10-16.60.","Growth driven by Mounjaro, Zepbound, and Verzenio; non-incretin revenue up 17% ex-Baqsimi rights sale.","Pipeline: FDA approval of Kisunla for Alzheimer's; tirzepatide submissions for sleep apnea; positive SUMMIT and QWINT trials.","Announced agreement to acquire Morphic Holding for oral integrin therapies; $5.3B manufacturing investment in Indiana."],"consensus_eps_estimate":null,"consensus_eps_actual":5.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":20070800000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215308,"accession_number":"0000059478-24-000164","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2024-07-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Eli Lilly CFO Anat Ashkenazi resigns; Gordon Brooks interim CFO from July 15","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Anat Ashkenazi resigned as EVP and CFO to pursue opportunity outside pharma; stays through July for transition.","Gordon Brooks, group VP controller and corporate strategy, named interim CFO effective July 15, 2024.","Brooks has 29-year Lilly career including CFO of U.S. Bio-Medicines and chief procurement officer.","No arrangements or family relationships; selection not pursuant to any agreement with outsiders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234615,"accession_number":"0000059478-24-000146","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Eli Lilly CFO Anat Ashkenazi resigns; to leave in July 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Anat Ashkenazi resigns as EVP and CFO to pursue a career opportunity outside the pharmaceutical industry.","She will continue in her role at full capacity and on the Executive Committee through July 2024.","An internal and external search for her successor is actively underway.","Ashkenazi served 23 years at Lilly, with 3 years as CFO overseeing growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234614,"accession_number":"0000059478-24-000127","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Eli Lilly annual meeting: directors elected, governance amendments fail","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All four director nominees elected; Katherine Baicker received 768.7M for, 4.8M against.","Advisory say-on-pay approved with ~95% of votes cast (734M for, 38.6M against).","Ratification of Ernst & Young as auditor for 2024 passed with 819.7M for (95.7% of votes cast).","Proposal to eliminate classified board failed with 70.1% for, short of 80% requirement.","All five shareholder proposals (lobbying, DEI, patents, human rights) each received <25% support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234613,"accession_number":"0000059478-24-000116","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2024-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lilly Q1 revenue up 26% to $8.77B; raises full-year guidance by $2B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 reported EPS $2.48 (up 66% YoY); non-GAAP EPS $2.58 (up 59% YoY), including $0.10 acquired IPR&D charges.","Revenue $8.77B, driven by Mounjaro, Zepbound, Verzenio, Jardiance; raised FY2024 revenue guidance by $2.0B.","Raises FY2024 reported EPS guidance to $13.05-$13.55 and non-GAAP EPS to $13.50-$14.00.","Pipeline progress: positive Phase 3 tirzepatide for OSA, mirikizumab submission for Crohn's, lebrikizumab resubmission.","Agreement to acquire injectable medicine manufacturing facility from Nexus Pharmaceuticals; broke ground on $2.5B German site."],"consensus_eps_estimate":null,"consensus_eps_actual":2.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":8768000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252479,"accession_number":"0001193125-24-029551","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2024-02-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lilly issues $6.5B in notes across five tranches with coupons 4.5%-5.1%","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $1B 4.5% Notes due 2027, $1B 4.5% Notes due 2029, $1.5B 4.7% Notes due 2034.","Also issued $1.5B 5.0% Notes due 2054 and $1.5B 5.1% Notes due 2064.","Net proceeds ~$6.45B after underwriting discounts; offering closed Feb 9, 2024.","Underwriters include BofA Securities, Barclays, Citigroup, Deutsche Bank, Mizuho.","Notes are unsecured and may be redeemed at Lilly's option under specified terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252478,"accession_number":"0000059478-24-000032","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2024-02-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lilly Q4 revenue up 28% to $9.35B; EPS $2.42 reported, $2.49 non-GAAP; FY2024 guidance issued","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $9,353.4M (+28% YoY); reported EPS $2.42 (+13%); non-GAAP EPS $2.49 (+19%).","New Products (Mounjaro, Zepbound) generated $2.49B revenue, up $2.19B YoY; Growth Products $5.27B (+9%).","2024 guidance: revenue $40.4–41.6B; EPS $11.80–12.30; non-GAAP EPS $12.20–12.70.","Pipeline: Zepbound and Jaypirca approved; tirzepatide Phase 2 NASH met primary endpoint; Verzenio Phase 3 mCRPC failed.","Acquisitions of POINT Biopharma and Mablink Biosciences closed; dividend raised 15% for 6th consecutive year."],"consensus_eps_estimate":null,"consensus_eps_actual":5.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":34124100000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":269985,"accession_number":"0000059478-23-000282","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lilly Q3 revenue up 37% to $9.5B; reported EPS loss $0.06 on $3.29 IPR&D charges, non-GAAP EPS $0.10","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $9,498.6M (+37% YoY) driven by Mounjaro, Verzenio, and $1.42B from olanzapine rights sale.","Reported net loss of $57.4M ($0.06 loss per share); non-GAAP net income $94.8M ($0.10 EPS).","Acquired IPR&D charges of $3.29/share and olanzapine gain of $1.22/share impacted EPS.","2023 reported EPS guidance lowered to $5.95-$6.15; non-GAAP EPS to $6.50-$6.70.","Completed acquisitions of DICE, Versanis, Emergence, Sigilon; agreed to buy POINT Biopharma."],"consensus_eps_estimate":null,"consensus_eps_actual":3.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":24770700000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":286962,"accession_number":"0000059478-23-000219","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lilly Q2 revenue $8.31B (+28%), EPS $1.95 (+86%), raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $8,312M, up 28% YoY; reported EPS $1.95 (+86%); non-GAAP EPS $2.11 (+69%, includes $0.43 from Baqsimi rights sale).","FY 2023 reported EPS guidance raised to $9.20-$9.40; non-GAAP EPS raised to $9.70-$9.90, up $1.02 and $1.05 respectively.","Mounjaro led New Products with $1.00B revenue; Growth Products up 16% to $4.93B, led by Verzenio, Jardiance, Taltz.","Pipeline progress: donanemab submitted to FDA/EMA for Alzheimer's; tirzepatide submitted for chronic weight management; mirikizumab approved in EU.","Announced agreements to acquire DICE Therapeutics, Sigilon Therapeutics, and Versanis Bio to expand autoimmune and cardiometabolic pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":3.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":15272100000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":306989,"accession_number":"0000059478-23-000165","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Lilly annual meeting: directors elected, charter amendments fail, all shareholder proposals defeated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Four directors (Kaelin, Ricks, Runge, Walker) elected with at least 742M votes for.","Advisory say-on-pay approved (742.6M for, 32.5M against); 1-year frequency adopted.","Ernst & Young ratified as auditor for 2023 (824.5M for, 32.8M against).","Charter amendments to eliminate classified board (70%) and supermajority voting (70%) failed to reach 80% of outstanding shares.","Nine shareholder proposals on lobbying, patents, abortion risk, DEI, and others all defeated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":306988,"accession_number":"0000059478-23-000160","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2023-04-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lilly Q1 revenue $6.96B (-11%); EPS $1.49 (-29%); core biz ex-COVID +10%; guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $6.96B, down 11% YoY; ex-COVID-19 antibodies up 10% on Mounjaro, Trulicity, Verzenio, Jardiance.","Reported EPS $1.49, down 29%; non-GAAP EPS $1.62, down 38%; both include $0.10 acquired IPR&D.","2023 reported EPS guidance raised to $8.18-$8.38; non-GAAP to $8.65-$8.85 (up $0.30).","New Products (Mounjaro, Jaypirca) contributed $573.6M; Growth Products rev $4.56B (+18%)."],"consensus_eps_estimate":null,"consensus_eps_actual":1.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":6960000000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":326071,"accession_number":"0000059478-23-000118","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2023-03-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Eli Lilly enters non-compete agreement with Daniel Skovronsky providing up to $5M payment","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Non-competition and non-solicitation agreement with Daniel Skovronsky executed March 17, 2023.","Restricts competitive activities and solicitation for up to 12 months post-termination.","Dr. Skovronsky eligible for up to $5 million payment if company enforces non-compete terms.","Terms consistent with company's Form of Non-Compete Payment Agreement in 2022 10-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":326070,"accession_number":"0001193125-23-048910","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2023-02-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Eli Lilly issues $4B in notes across four tranches, net proceeds ~$3.96B","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $750M 5.000% notes due 2026, $1B 4.700% notes due 2033, $1.25B 4.875% notes due 2053, $1B 4.950% notes due 2063.","Net proceeds of approximately $3.96B after underwriting discounts and expenses.","Underwriters: J.P. Morgan, Credit Suisse, Goldman Sachs, Morgan Stanley.","Notes are senior unsecured obligations; redeemable at company's option upon certain events."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":326069,"accession_number":"0000059478-23-000025","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2023-02-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lilly Q4 2022 EPS $2.14; revenue down 9%; core up 5%; 2023 guidance $7.90-$8.10","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 revenue $7.30B (-9% YoY); ex-COVID antibodies revenue +5% (+10% constant currency).","Reported EPS $2.14 (+13%); non-GAAP EPS $2.09 (-4%); includes $0.23 acquired IPR&D charges.","Key growth products (Verzenio, Mounjaro, Jardiance, Taltz, Trulicity, etc.) grew 21% to 70% of revenue.","2023 EPS guidance: reported $7.90-$8.10; non-GAAP $8.35-$8.55; mid-teen core revenue growth expected.","Pipeline: FDA approved Jaypirca for MCL; rolling submission tirzepatide in obesity; Jardiance CKD submissions."],"consensus_eps_estimate":null,"consensus_eps_actual":6.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":28541400000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":343786,"accession_number":"0000059478-22-000277","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2022-12-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lilly guides 2023 revenue $30.3B-$30.8B, EPS $7.65-$7.85; plans four new drug launches","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["2023 revenue guidance $30.3B-$30.8B, up from 2022 reaffirmed $28.5B-$29.0B.","2023 reported EPS $7.65-$7.85; non-GAAP EPS $8.10-$8.30; 2022 reaffirmed $6.50-$6.65 reported.","Plans to launch donanemab, mirikizumab, lebrikizumab, pirtobrutinib; potential tirzepatide obesity submission.","Fifth consecutive 15% annual dividend increase; R&D spend $8.2B-$8.4B vs $7.1B-$7.3B 2022.","Gross margin ~77% reported, ~79% non-GAAP; tax rate ~16%; Alimta LOE and FX headwinds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":343785,"accession_number":"0000059478-22-000248","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2022-11-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lilly Q3 2022: revenue up 2% to $6.94B, reported EPS $1.61 (+32%), Mounjaro launch strong","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $6,941.6M (+2% reported, +7% constant currency); total volume +14%.","Reported EPS $1.61 (+32%); non-GAAP EPS $1.98 (+12%); both inclusive of $0.06 acquired IPR&D charges.","Mounjaro U.S. revenue $97.3M in first full quarter; plus $86.0M from Japan collaboration agreement.","Key growth products (Verzenio, Trulicity, Mounjaro, etc.) grew 19% and represented 70% of revenue (ex-COVID antibodies).","2022 EPS guidance updated: reported $6.50-$6.65, non-GAAP $7.70-$7.85, inclusive of $0.67 charges."],"consensus_eps_estimate":null,"consensus_eps_actual":4.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":21239600000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":343784,"accession_number":"0000059478-22-000233","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2022-10-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Lilly expects $62.4M pre-tax IPR&D and milestone charge in Q3 2022, $0.06 EPS impact","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Estimated $62.4M pre-tax charge for acquired IPR&D and development milestones in Q3 2022.","Charge translates to $0.06 per share on both GAAP and non-GAAP basis.","Results for Q3 2022 not yet finalized; actuals may differ.","Company does not forecast such charges due to uncertainty of future transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":360285,"accession_number":"0000059478-22-000194","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lilly Q2 EPS $1.05 ($1.25 non-GAAP); revenue down 4% to $6.49B; key growth products up 20%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $6,488M (-4% YoY; -1% constant currency); core revenue up 6% excluding Alimta, Cialis rights sale, COVID antibodies.","Reported EPS $1.05 (-31%); non-GAAP EPS $1.25 (-32%); both include $0.46 acquired IPR&D charges.","Key growth products (Trulicity, Verzenio, Jardiance etc.) grew 20% to 67% of revenue (ex COVID antibodies).","2022 guidance: reported EPS $6.96-$7.11, non-GAAP $7.90-$8.05; revenue guidance unchanged.","FDA accepted donanemab (Alzheimer's) and pirtobrutinib (MCL) with Priority Review; Mounjaro approved for T2D; Olumiant for alopecia areata."],"consensus_eps_estimate":null,"consensus_eps_actual":3.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":14298000000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":379301,"accession_number":"0000059478-22-000143","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2022-05-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Eli Lilly elects Dr. Mary Lynne Hedley to board effective May 15, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Mary Lynne Hedley elected to Lilly's Board of Directors, effective May 15, 2022.","She will serve on the Science & Technology Committee and the Ethics and Compliance Committee.","Hedley is a Senior Scientific Fellow at Broad Institute; previously co-founded TESARO (acquired by GSK) and served as President/COO.","Board determined she is independent under NYSE standards and company guidelines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":379300,"accession_number":"0000059478-22-000138","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2022-05-04T23:59:59+00:00","items":["3.03","5.03","5.07","9.01"],"status":"ready","headline":"Lilly shareholders approve bylaw amendment power; classified board/supermajority proposals fail","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to allow bylaw amendments by majority vote of outstanding shares (669M for, 113M against).","Proposals to eliminate classified board and supermajority voting failed, each short of 80% required (approx. 69% for).","Say-on-pay advisory vote passed with 737.9M for; Ernst & Young ratified as auditor for 2022.","Independent board chair and three lobbying disclosure shareholder proposals all defeated.","Three director nominees elected: Alvarez, Johnson, Luciano (each with over 746M for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":379299,"accession_number":"0000059478-22-000130","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2022-04-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lilly Q1 2022 revenue up 15% to $7.81B; reported EPS $2.10, non-GAAP $2.62; raises guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $7.81B (+15% YoY); volume growth 20%; core product sales up 13 ppt.","Reported EPS $2.10 (+41%); non-GAAP EPS $2.62 (+63%); both include $0.15 charges.","2022 EPS guidance raised: reported $7.30-$7.45; non-GAAP $8.15-$8.30.","Tirzepatide SURMOUNT-1 obesity Phase 3: up to 22.5% weight loss; 63% of high-dose group lost ≥20% body weight.","FDA accepted mirikizumab submission for UC; Jardiance EMPA-KIDNEY trial stopped early for positive efficacy."],"consensus_eps_estimate":null,"consensus_eps_actual":2.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":7810000000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":379298,"accession_number":"0000059478-22-000117","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2022-04-14T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Lilly to change non-GAAP presentation; anticipates ~$165M IPR&D charge for Q1 2022, $0.15 EPS impact","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Will no longer adjust for upfront charges/development milestones on acquired IPR&D projects in non-GAAP measures.","Anticipates ~$165 million in such charges for Q1 2022, impacting EPS by ~$0.15.","Change follows SEC guidance; historical financials to be restated on company website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":397498,"accession_number":"0000059478-22-000016","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2022-02-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lilly Q4 2021 non-GAAP EPS $2.49 (+8%), revenue $8.0B +8%; 2022 guidance reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $7,999.9M (+8% YoY); non-GAAP EPS $2.49 (+8%).","Full-year revenue $28,318.4M (+15%); non-GAAP EPS $8.16 (+20%).","COVID-19 antibody revenue $1.06B in Q4, $2.24B for full year.","Key growth products (Trulicity, Taltz, Verzenio, Jardiance, Olumiant) contributed 14 ppt revenue growth ex-COVID.","2022 EPS guidance: GAAP $8.00-$8.15, non-GAAP $8.50-$8.65; dividend raised 15%."],"consensus_eps_estimate":null,"consensus_eps_actual":6.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":28318400000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":397497,"accession_number":"0001193125-22-022446","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2022-01-31T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Eli Lilly redeems €600M of 1.000% Notes due 2022 on March 2","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Redeems all €600,000,000 aggregate principal of 1.000% Notes due 2022.","Redemption date is March 2, 2022 at par plus accrued interest.","Notice delivered by Deutsche Bank Trust Company Americas as trustee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":416485,"accession_number":"0001193125-21-359144","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2021-12-16T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Lilly amends bylaws to revise shareholder nomination procedures and meeting rules","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Revised procedures and disclosure requirements for director nominations and shareholder proposals.","Annual meeting date now set by Board of Directors instead of fixed third Monday in April.","Meetings may be held by remote communication in addition to or instead of physical meetings.","Chair of shareholder meeting may prescribe conduct rules and adjourn with or without quorum.","Adopted gender-neutral language and made administrative, modernizing, and clarifying changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":416484,"accession_number":"0001193125-21-357380","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2021-12-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lilly raises 2021 revenue guidance to $28.0B-$28.3B; 2022 EPS seen at $8.00-$8.15","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2021 revenue guidance raised to $28.0B-$28.3B (from $27.2B-$27.6B); non-GAAP EPS raised to $8.15-$8.20.","2022 revenue guidance $27.8B-$28.3B; reported EPS $8.00-$8.15; non-GAAP EPS $8.50-$8.65.","Initiated rolling FDA submission for pirtobrutinib in MCL; completion in 2022, regulatory action early 2023.","Plans new phase 3 studies for tirzepatide in obesity outcomes, sleep apnea, and kidney disease; donanemab biomarker data disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":416483,"accession_number":"0000059478-21-000213","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2021-10-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lilly Q3 revenue up 18% to $6.77B; non-GAAP EPS $1.94 (+38%); pipeline advances with tirzepatide, donanemab","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $6.773B (+18% YoY); GAAP EPS $1.22 (-8%), non-GAAP EPS $1.94 (+38%).","Key growth products (Trulicity +45%, Verzenio +43%) drove 17pp of growth; COVID-19 antibody revenue $423.5M.","Submitted tirzepatide NDA for type 2 diabetes with priority review voucher; initiated rolling submission for donanemab in early Alzheimer's.","FDA approved Verzenio for high-risk early breast cancer and Jardiance for HFrEF; positive Phase 3 for lebrikizumab in atopic dermatitis.","Repurchased higher-cost debt ($405.2M charge); issued €600M sustainability bond."],"consensus_eps_estimate":null,"consensus_eps_actual":4.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":20318500000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":434045,"accession_number":"0001193125-21-270093","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2021-09-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Eli Lilly issues €1.8B and £250M in four tranches of notes due 2033-2061","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issues €600M 0.500% notes due 2033, €500M 1.125% notes due 2051, €700M 1.375% notes due 2061, and £250M 1.625% notes due 2043.","Net proceeds: ~€596.3M (2033), ~€485.7M (2051), ~€680.0M (2061), ~£243.3M (2043).","Closing expected September 14, 2021; underwriters include Merrill Lynch, Barclays, BNP Paribas, Citi, Deutsche Bank."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":434044,"accession_number":"0000059478-21-000190","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2021-08-25T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Carolyn Bertozzi resigns from Lilly board due to Lycia Therapeutics collaboration","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Carolyn Bertozzi resigned as independent director effective August 23, 2021, in connection with Lilly's collaboration and licensing agreement with Lycia Therapeutics.","Bertozzi served on the board since 2017, including on Science and Technology and Ethics and Compliance committees.","Resignation did not arise from any disagreement with Lilly's operations, policies, or practices.","Lilly's chairman thanked Bertozzi for her service, citing her scientific expertise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":434043,"accession_number":"0000059478-21-000175","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2021-08-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Lilly restructures leadership; Zulueta retiring, Yuffa to lead International, new Neuroscience & Immunology units","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Alfonso Zulueta, President of Lilly International, to retire effective Dec 26, 2021; succeeded by Ilya Yuffa.","Lilly Bio-Medicines splits into two units: Lilly Neuroscience (led by Anne White) and Lilly Immunology (led by Patrik Jonsson).","Jake Van Naarden promoted to CEO of Loxo Oncology at Lilly and President of Lilly Oncology, joins executive committee.","Donanemab (Alzheimer's) BLA submission planned under accelerated approval pathway; tirzepatide (type 2 diabetes) potential launch cited.","Changes effective Sept 5, 2021; CEO David Ricks cites focus on late-stage pipeline and breakthrough medicines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":434042,"accession_number":"0000059478-21-000168","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2021-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lilly Q2 revenue $6.74B (+23% YoY); non-GAAP EPS $1.87 (+29%); updates 2021 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $6.74B (+23% YoY); volume growth 22%; non-GAAP EPS $1.87 (+29% YoY).","Reported EPS $1.53 (-1% YoY) due to $423M COVID antibody inventory charge.","2021 GAAP EPS guidance updated to $6.73-$6.93; non-GAAP unchanged at $7.80-$8.00.","Key products: Trulicity +25%, Taltz +44%, Verzenio +64%; pipeline milestones for tirzepatide, Jardiance, donanemab.","Board authorizes $5B share repurchase; acquires Protomer; global collaboration with MiNA."],"consensus_eps_estimate":null,"consensus_eps_actual":3.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":13545700000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-08-03T23:59:59+00:00|434042"}